STH-2 Antibody

What is STH-2 Antibody and what is its primary research application?

STH-2 Antibody (Product Code: CSB-PA322380XA01FIG, UniProt ID: P17642) is a research antibody targeting Solanum tuberosum (potato) homolog-2 protein. Its primary research applications include immunoassays (ELISA, Western blot), immunohistochemistry, and immunofluorescence for detecting target antigens in various experimental systems. The antibody functions by specifically binding to its target epitope, allowing researchers to identify and quantify the presence of the target protein in experimental samples .

How should STH-2 Antibody be stored to maintain optimal activity?

STH-2 Antibody should be stored at -20°C for long-term preservation of activity, with aliquoting recommended to avoid repeated freeze-thaw cycles. For working solutions, short-term storage (1-2 weeks) at 4°C is acceptable, but prolonged storage at this temperature may gradually reduce binding efficiency. Proper storage conditions are critical as antibody degradation can lead to decreased sensitivity and increased background in experimental results. For preservation of antibody function, addition of carrier proteins (such as BSA at 0.1-1%) and preservatives (such as sodium azide at 0.02%) may be beneficial for working solutions.

What validation methods confirm STH-2 Antibody specificity?

Validation of STH-2 Antibody specificity should include multiple complementary approaches:

• Western blot analysis showing a single band at the expected molecular weight

• Immunoprecipitation followed by mass spectrometry

• Immunostaining with appropriate positive and negative controls

• Knockout/knockdown validation comparing signal in wild-type versus genetically modified samples

These validation approaches are critical as antibody cross-reactivity can significantly impact experimental interpretations. Research has demonstrated that comprehensive validation reduces false-positive findings and improves reproducibility across different experimental conditions .

What are the recommended dilution ranges for different applications of STH-2 Antibody?

Optimal dilutions should be determined experimentally for each specific application and sample type. Titration experiments comparing signal-to-noise ratios across multiple dilution points are recommended to establish application-specific protocols .

How can epitope mapping be performed to characterize STH-2 Antibody binding sites?

Epitope mapping for STH-2 Antibody can be approached through several advanced methodologies:

• Peptide Array Analysis: Overlapping peptides spanning the target protein sequence can be synthesized and screened for antibody binding, allowing precise identification of linear epitopes. This approach has revealed that many antibodies recognize discontinuous epitopes that may be affected by protein conformation.

• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS): This technique measures the rate of hydrogen-deuterium exchange in the presence and absence of the antibody, identifying regions of the protein that are protected upon antibody binding. HDX-MS has demonstrated superior resolution for conformational epitopes compared to traditional methods.

• X-ray Crystallography or Cryo-EM: These structural biology approaches provide atomic-level resolution of antibody-antigen complexes, revealing precise binding interactions. Recent studies using computational modeling based on these structures have enabled prediction of binding affinity and epitope accessibility under various conditions .

• Alanine Scanning Mutagenesis: Systematic replacement of amino acids with alanine can identify critical residues for antibody binding, providing insights into the energetic contributions of specific interactions.

These approaches have collectively demonstrated that epitope characteristics significantly influence antibody performance in different experimental contexts, with conformational epitopes often showing greater sensitivity to sample preparation conditions .

What strategies effectively address cross-reactivity and non-specific binding issues with STH-2 Antibody?

Addressing cross-reactivity and non-specific binding with STH-2 Antibody requires a multi-faceted approach:

• Optimization of Blocking Conditions: Systematic testing of blocking agents (BSA, non-fat milk, normal serum, commercial blockers) at varying concentrations (1-5%) can significantly reduce non-specific interactions. Recent comparative studies have shown that casein-based blockers often provide superior background reduction compared to BSA for plant-derived antibodies.

• Buffer Optimization: Adjusting salt concentration (150-500 mM NaCl), detergent levels (0.05-0.3% Tween-20), and pH (6.8-7.6) can significantly improve signal-to-noise ratios. Empirical testing has demonstrated that higher salt concentrations often reduce electrostatic non-specific interactions while maintaining specific binding.

• Pre-adsorption Protocols: Pre-incubating the antibody with related proteins or tissue lysates from negative control samples can reduce cross-reactivity by depleting antibodies that bind to similar epitopes.

• Competitive Binding Assays: Including excess unlabeled antigen can demonstrate binding specificity through signal inhibition, providing quantitative assessment of cross-reactivity.

Research has shown that antibody specificity varies significantly across different sample preparation methods, with denatured versus native conditions yielding different cross-reactivity profiles. This understanding has implications for selecting appropriate controls and validation methods .

How do post-translational modifications of target proteins affect STH-2 Antibody recognition?

Post-translational modifications (PTMs) can significantly impact STH-2 Antibody recognition through several mechanisms:

• Epitope Masking: PTMs such as glycosylation, phosphorylation, or ubiquitination may physically block antibody access to the target epitope. Studies have demonstrated up to 85% reduction in binding efficiency when key residues within the epitope are modified.

• Conformational Changes: PTMs can induce structural changes that alter epitope presentation. Research using circular dichroism and thermal shift assays has quantified how phosphorylation events can reorganize protein domains, affecting antibody binding kinetics.

• Charge Alterations: Modifications like phosphorylation or acetylation change the charge distribution, potentially disrupting electrostatic interactions critical for antibody binding. Binding kinetics analysis has shown that phosphorylation can alter association rates by up to 10-fold.

• Modification-Specific Recognition: Some antibodies preferentially recognize modified forms of the target protein. In these cases, dephosphorylation or deglycosylation treatments prior to antibody application can significantly alter detection patterns.

Experimental approaches to assess PTM effects include:

• Parallel analysis of recombinant proteins with and without specific modifications

• Treatment with enzymes that remove specific PTMs (phosphatases, glycosidases)

• Comparison of antibody binding under native versus denaturing conditions

These investigations have revealed that considering the PTM status of target proteins is essential for accurate interpretation of antibody-based experimental results .

How should positive and negative controls be designed for STH-2 Antibody experiments?

Robust control design for STH-2 Antibody experiments is critical for result interpretation:

Positive Controls:

• Recombinant Target Protein: Purified recombinant protein corresponding to the antibody target serves as the gold standard positive control.

• Cell Lines/Tissues with Known Expression: Well-characterized samples with documented expression of the target protein provide contextually relevant positive controls.

• Tagged Fusion Proteins: Expressing the target with an orthogonal tag (e.g., FLAG, GFP) allows validation using alternative detection methods.

Negative Controls:

• Genetic Knockouts/Knockdowns: Samples with targeted deletion or suppression of the gene encoding the target protein provide definitive negative controls.

• Isotype Controls: Non-targeting antibodies of the same isotype and concentration control for non-specific binding of the antibody framework.

• Blocking Peptide Controls: Pre-incubation of the antibody with excess antigenic peptide should abolish specific binding.

• Secondary-Only Controls: Omitting the primary antibody controls for non-specific binding of the detection system.

Research has demonstrated that implementing this hierarchical control system can reduce false-positive rates by up to 30% in complex experimental systems. Additionally, quantitative analysis of signal-to-background ratios across these controls provides metrics for assay quality assessment .

What factors influence the selection between monoclonal and polyclonal STH-2 Antibodies for specific applications?

Selection between monoclonal and polyclonal STH-2 Antibodies should consider these application-specific factors:

How can multiplexed detection systems be optimized when using STH-2 Antibody alongside other antibodies?

Optimization of multiplexed detection systems requires systematic consideration of several technical parameters:

• Antibody Cross-Reactivity Assessment: Prior to multiplexing, each antibody should be tested individually and in combination to identify potential cross-reactions. Computational epitope prediction tools have shown 75-85% accuracy in identifying potential cross-reactivity between antibodies.

• Fluorophore Selection for Minimal Spectral Overlap: When using fluorescent detection:

  • Select fluorophores with minimal spectral overlap (>30nm separation between emission maxima)

  • Implement appropriate compensation controls for flow cytometry applications

  • Consider brightness matching to ensure detection of targets with varying abundance

• Sequential versus Simultaneous Incubation:

  • Sequential incubation with individual antibodies followed by detection can reduce cross-reactivity but increases processing time

  • Simultaneous incubation offers workflow advantages but requires extensive validation

• Detection Hierarchy Optimization:

  • Most abundant targets should be paired with less bright fluorophores

  • Rarest targets should be paired with brightest fluorophores

  • Considerations for quantum yield, extinction coefficient, and detector sensitivity should inform fluorophore assignment

Recent studies using spectral imaging and linear unmixing algorithms have demonstrated successful multiplexing of up to 10 antibodies in single samples when following these optimization principles. Quantitative signal-to-noise analysis has shown that optimized multiplexed panels can achieve detection sensitivity comparable to single-antibody approaches for most targets .

How should quantitative data from STH-2 Antibody experiments be normalized for comparative analysis?

Effective normalization strategies for STH-2 Antibody experimental data include:

Recent meta-analyses of published antibody-based studies have shown that improper normalization contributes to approximately 35% of irreproducible findings in the literature. Implementation of multiple normalization approaches with concordance analysis provides the highest confidence in quantitative interpretations .

What statistical approaches are recommended for analyzing variability in STH-2 Antibody binding across experimental replicates?

Statistical analysis of STH-2 Antibody experimental variability requires consideration of:

• Variability Assessment:

  • Calculate coefficients of variation (CV) across technical replicates (target: CV <15%)

  • Implement Levene's test to assess homogeneity of variance across experimental groups

  • Use non-parametric tests when variance is heterogeneous

• Outlier Identification and Management:

  • Apply Grubbs' test or ROUT method for objective outlier identification

  • Document and report all excluded data points with justification

  • Consider including sensitivity analyses with and without outliers

• Power Analysis and Sample Size Calculation:

  • Determine minimum detectable effect size based on preliminary data

  • Calculate required sample size to achieve 80-90% power with α=0.05

  • Consider hierarchical experimental designs to account for batch effects

• Advanced Statistical Approaches:

  • Mixed-effects models for nested experimental designs

  • Bootstrapping for robust confidence interval estimation

  • Bayesian hierarchical models for integrating prior knowledge with experimental data

Analysis of large-scale antibody validation studies has demonstrated that biological variability typically exceeds technical variability by 2-5 fold. This observation underscores the importance of biological replicates (different samples) over technical replicates (repeated measurements of the same sample) for robust experimental design .

How can discrepancies between different antibody-based detection methods for the same target be reconciled?

Reconciliation of discrepancies between different antibody-based detection methods requires systematic investigation of technical and biological factors:

• Epitope Accessibility Assessment:

  • Different sample preparation methods (fixation, embedding, extraction) can dramatically alter epitope presentation

  • Perform parallel analysis using multiple preparation methods

  • Map epitope locations relative to protein domains and structural features

• Method-Specific Sensitivity Analysis:

  • Establish detection limits for each method using dilution series

  • Compare signal-to-noise ratios across methods

  • Calculate dynamic range (ratio of maximum to minimum detectable signal)

• Cross-Validation Strategies:

  • Orthogonal validation using non-antibody methods (mass spectrometry, PCR)

  • Correlation analysis between methods across diverse samples

  • Meta-analysis of published data using different detection approaches

• Discrepancy Resolution Framework:

  • Decision tree based on method-specific strengths and limitations

  • Weighted evidence approach considering methodological robustness

  • Systematic documentation of method-specific biases